Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves’ disease

PLoS ONE

Volumn 13, Issue 4, 2018, Pages

  Mizuguchi, Yuki ^a   Morimoto, Satoshi ^a   Kimura, Shihori ^a   Takano, Noriyoshi ^a   Yamashita, Kaoru ^a   Seki, Yasufumi ^a   Bokuda, Kanako ^a   Yatabe, Midori ^a   Yatabe, Junichi ^a   Watanabe, Daisuke ^a   Ando, Takashi ^a   Ichihara, Atsuhiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; PROPYLTHIOURACIL; PRORENIN RECEPTOR; THIAMAZOLE; TRIACYLGLYCEROL; ATP6AP2 PROTEIN, HUMAN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANTITHYROID AGENTS; BIOMARKERS; BODY MASS INDEX; FEMALE; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; TRIGLYCERIDES; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 85045052465     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0195464     Document Type: Article

References (29)

1. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. The Journal of clinical investigation. 2002; 109(11):1417–27. Epub 2002/06/05. https://doi.org/10.1172/JCI14276 PMID: 12045255.
2. Advani A, Kelly DJ, Cox AJ, White KE, Advani SL, Thai K, et al. The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension. 2009; 54(2):261–9. Epub 2009/06/24. https://doi.org/10.1161/HYPERTENSIONAHA.109.128645 PMID: 19546380.
3. Ludwig J, Kerscher S, Brandt U, Pfeiffer K, Getlawi F, Apps DK, et al. Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules. J Biol Chem. 1998; 273(18):10939–47. PMID: 9556572.
4. Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, Kurauchi-Mito A, et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circulation research. 2010; 107(1):30–4. Epub 2010/06/24. https://doi.org/10.1161/CIRCRESAHA.110.224667PMID: 20570919.
5. Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science. 2010; 327(5964):459–63. Epub 2010/01/23. https://doi.org/10.1126/science.1179802 PMID: 20093472.
6. Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Murohashi-Bokuda K, et al. Possible roles of human (pro)renin receptor suggested by recent clinical and experimental findings. Hypertension research: official journal of the Japanese Society of Hypertension. 2010; 33(3):177–80. Epub 2009/12/ 19. https://doi.org/10.1038/hr.2009.214 PMID: 20019703.
7. Watanabe N, Morimoto S, Fujiwara T, Suzuki T, Taniguchi K, Mori F, et al. Prediction of gestational diabetes mellitus by soluble (pro)renin receptor during the first trimester. The Journal of clinical endocrinology and metabolism. 2013; 98(6):2528–35. Epub 2013/05/31. https://doi.org/10.1210/jc.2012-4139PMID: 23720787.
8. Morimoto S, Ando T, Niiyama M, Seki Y, Yoshida N, Watanabe D, et al. Serum soluble (pro)renin receptor levels in patients with essential hypertension. Hypertension research: official journal of the Japanese Society of Hypertension. 2014. Epub 2014/03/22. https://doi.org/10.1038/hr.2014.46 PMID: 24646643.
9. Amari Y, Morimoto S, Nakajima F, Ando T, Ichihara A. Serum Soluble (Pro)Renin Receptor Levels in Maintenance Hemodialysis Patients. PLoS One. 2016; 11(7):e0158068. https://doi.org/10.1371/journal.pone.0158068 PMID: 27367528.
10. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016; 388(10047):906–18. https://doi.org/10.1016/S0140-6736(16)00278-6 PMID: 27038492.
11. Brandt F, Almind D, Christensen K, Green A, Brix TH, Hegedus L. Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a danish nationwide register-based cohort study of twins and singletons. J Clin Endocrinol Metab. 2012; 97(11):4123–9. https://doi.org/10.1210/jc.2012-2268 PMID: 22930783.
12. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013; 98(9):3671–7. https://doi.org/10.1210/jc.2013-1954 PMID: 23824415.
13. Ruf J, Carayon P. Structural and functional aspects of thyroid peroxidase. Arch Biochem Biophys. 2006; 445(2):269–77. https://doi.org/10.1016/j.abb.2005.06.023 PMID: 16098474.
14. Ma C, Xie J, Wang H, Li J, Chen S. Radioiodine therapy versus antithyroid medications for Graves’ disease. Cochrane Database Syst Rev. 2016; 2:CD010094. https://doi.org/10.1002/14651858.CD010094.pub2 PMID: 26891370.
15. Cooper DS. Antithyroid drugs. N Engl J Med. 2005; 352(9):905–17. https://doi.org/10.1056/NEJMra042972 PMID: 15745981.
16. Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves’ Hyperthyroidism. J Clin Endocrinol Metab. 2016; 101(4):1381–9. https://doi.org/10.1210/jc.2015-3644 PMID: 26863422.
17. Andersen SL, Olsen J, Laurberg P. Antithyroid Drug Side Effects in the Population and in Pregnancy. J Clin Endocrinol Metab. 2016; 101(4):1606–14. https://doi.org/10.1210/jc.2015-4274 PMID: 26815881.
18. Xiao F, Lin M, Huang P, Zeng J, Zeng X, Zhang H, et al. Elevated Serum Fibroblast Growth Factor 21 Levels in Patients With Hyperthyroidism. The Journal of clinical endocrinology and metabolism. 2015; 100(10):3800–5. Epub 2015/08/05. https://doi.org/10.1210/jc.2015-1797 PMID: 26241324.
19. Barreto-Chaves ML, Carrillo-Sepulveda MA, Carneiro-Ramos MS, Gomes DA, Diniz GP. The crosstalk between thyroid hormones and the Renin-Angiotensin System. Vascul Pharmacol. 2010; 52(3–4):166–70. https://doi.org/10.1016/j.vph.2009.10.009 PMID: 19857605.
20. Kanda A, Noda K, Ishida S. ATP6AP2/(pro)renin receptor contributes to glucose metabolism via stabilizing the pyruvate dehydrogenase E1 beta subunit. The Journal of biological chemistry. 2015; 290 (15):9690–700. Epub 2015/02/28. https://doi.org/10.1074/jbc.M114.626713 PMID: 25720494.
21. Maruyama N, Segawa T, Kinoshita N, Ichihara A. Novel sandwich ELISA for detecting the human soluble (pro)renin receptor. Frontiers in bioscience. 2013; 5:583–90. Epub 2013/01/02. PMID: 23277014.
22. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2009; 53(6):982–92. Epub 2009/04/03. https://doi.org/10.1053/j.ajkd.2008.12.034PMID: 19339088.
23. Marchant C, Brown L, Sernia C. Renin-angiotensin system in thyroid dysfunction in rats. J Cardiovasc Pharmacol. 1993; 22(3):449–55. PMID: 7504137.
24. Montiel M, Jimenez E, Navaez JA, Morell M. Aldosterone and plasma renin activity in hyperthyroid rats: effects of propranolol and propylthiouracil. J Endocrinol Invest. 1984; 7(6):559–62. https://doi.org/10.1007/BF03349486 PMID: 6397501.
25. Kobori H, Ichihara A, Suzuki H, Miyashita Y, Hayashi M, Saruta T. Thyroid hormone stimulates renin synthesis in rats without involving the sympathetic nervous system. Am J Physiol. 1997; 272(2 Pt 1): E227–32. https://doi.org/10.1152/ajpendo.1997.272.2.E227 PMID: 9124327.
26. Kobori H, Ichihara A, Suzuki H, Takenaka T, Miyashita Y, Hayashi M, et al. Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism. Am J Physiol. 1997; 273(2 Pt 2): H593–9. https://doi.org/10.1152/ajpheart.1997.273.2.H593 PMID: 9277473.
27. Sernia C, Marchant C, Brown L, Hoey A. Cardiac angiotensin receptors in experimental hyperthyroidism in dogs. Cardiovasc Res. 1993; 27(3):423–8. PMID: 8490942.
28. Oshima Y, Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Bokuda K, et al. Prorenin receptor is essential for normal podocyte structure and function. Journal of the American Society of Nephrology: JASN. 2011; 22(12):2203–12. Epub 2011/11/05. https://doi.org/10.1681/ASN.2011020202 PMID: 22052048.
29. Ashford TP, Porter KR. Cytoplasmic components in hepatic cell lysosomes. J Cell Biol. 1962; 12:198–202. PMID: 13862833.